Status:
COMPLETED
Faslodex Specific Clinical Experience Investigation
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
The purpose of this study is to confirm the safety profile such as the frequency of serious adverse events or any unexpected adverse events and overall efficacy of Faslodex for long term treatment in ...
Detailed Description
MC MD
Eligibility Criteria
Inclusion
- Patients treated with Faslodex for the first time due to postmenopausal breast cancer
Exclusion
- None
Key Trial Info
Start Date :
February 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2015
Estimated Enrollment :
660 Patients enrolled
Trial Details
Trial ID
NCT01501266
Start Date
February 1 2012
End Date
January 1 2015
Last Update
May 10 2016
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aichi, Japan
2
Research Site
Akita, Japan
3
Research Site
Aomori, Japan
4
Research Site
Chiba, Japan